Advanced Oncotherapy PLC
LSE:AVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0.03 (101% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.7 | GBX1.93 |
0%
|
| Industry Average | 0 | GBX-0.03 |
-101%
|
| Country Average | 0 | GBX-0.02 |
-101%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX51.5m
|
/ |
Jul 2022
£-30.1m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2022
£-25.1m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2023
£-21m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2024
£-3.9m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2025
£11.7m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2026
£24.9m
|
= |
|
|
GBX51.5m
|
/ |
Dec 2027
£45.2m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Advanced Oncotherapy PLC
LSE:AVO
|
8.7m GBP | -1.7 | -0.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 45.1 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 14 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 12.9 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 19.9 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 29.9 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 10 | 25.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Advanced Oncotherapy PLC
Glance View
Advanced Oncotherapy Plc engages in the development of proton therapy systems. The firm is focused on developing and supplying technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to the patient's healthy tissues. The linear design of LIGHT allows for an active longitudinal modulation along the proton beam axis, and the variation of the proton beam by electronic means during cancer treatment. The feature of LIGHT offers hospitals and treatment centers the flexibility to customize cancer treatment plans based on a range of energies. This could provide an alternative to passive modulation, that degrades the beam along its path, causing it to lose integrity. In addition, a dynamic transversal modulation allows a precise three dimensional (3D) treatment of the tumors via the spot scanning technique.
